A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)
This study is testing a new way to treat Acute Myeloid Leukemia (AML) by combining two common cancer drugs with special immune cells called Natural Killer (NK) cells. The goal is to see if these healthy donor cells can help your own immune system better identify and destroy stubborn leukemia cells.
This trial is for adults (18+) with AML or a related condition called MDS/AML that has returned or did not respond well to previous standard treatments. Participants must be in a state where their disease has not been controlled by earlier therapies.
You will receive a combination of two medications—Azacitidine and Venetoclax—along with an infusion of healthy donor NK cells. Your medical team will monitor you closely to see how your body responds to the treatment and to ensure your safety.
The study is currently recruiting patients at medical centers in Cleveland, Ohio, and Houston, Texas. You can discuss with your doctor if traveling to these locations is a possibility for your care.
- 1Uses healthy donor immune cells to help fight leukemia.
- 2Designed for patients who have already tried other treatments without success.
- 3Requires a review of your specific genetic profile and overall health status to join.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.